Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

57.38 -0.83 (-1.43%)
Official Closing Price Updated: 7:00 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,273,142
Open 58.16
Bid (Size) 57.23 (1)
Ask (Size) 58.15 (2)
Prev. Close 58.21
Today's Range 57.22 - 58.42
52wk Range 39.35 - 61.10
Shares Outstanding 2,222,113,553
Dividend Yield 4.18%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
Is NYSE:BMY suited for dividend investing?
Analyzing BRISTOL-MYERS SQUIBB CO (NYSE:BMY)'s Dividend Potential. 
Via Chartmill

Performance

YTD
+1.04%
+1.04%
1 Month
-5.31%
-5.31%
3 Month
-3.19%
-3.19%
6 Month
+16.96%
+16.96%
1 Year
+13.60%
+13.60%

More News

Read More
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
Uncover the latest developments among S&P500 stocks in today's session.
Via Chartmill
Exploring the top movers within the S&P500 index during today's session.
Via Chartmill
Bristol Myers Colorectal Cancer Treatment Goes Under Priority FDA Review
Via Benzinga
Exposures Product Safety
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
From Bristol Myers Squibb
Via Business Wire
NYSE:BMY: good value for what you're paying.
Via Chartmill
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
Via Benzinga
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
Via Stocktwits
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
Via Talk Markets
Topics Stocks / Equities
Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer
Via Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich
Via Benzinga
Topics Government
Exposures Political
Nuclear Power Is Solving the World’s Looming Energy Crisis
Via InvestorPlace
Topics Government World Trade
Exposures Political Tariff
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
My “Two-Step” Plan for Surviving Shaky Markets – and Coming Out Ahead
Via InvestorPlace
Topics Government World Trade
Exposures Political Tariff
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
From Bristol Myers Squibb
Via Business Wire
How to Read Trump’s Tariff Playbook – and Prepare for His Next Moves
Via InvestorPlace
Topics Government World Trade
Exposures Political Tariff
Earnings To Watch: Zoetis (ZTS) Reports Q4 Results Tomorrow
Via StockStory
Organon (OGN) Q4 Earnings Report Preview: What To Look For
Via StockStory
Gapping S&P500 stocks in Monday's session
Via Chartmill
What's Going On With Bristol Myers Squibb Stock On Monday?
Via Benzinga
Exposures Product Safety
Royalty Pharma Earnings: What To Look For From RPRX
Via StockStory
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.